Related Experiment Video
Updated: Aug 17, 2026

Determining Ciliary Function and Membrane Impermeability of the Pseudostratified Lung Airway Epithelium
Published on: February 21, 2025
Recovery of the ciliated epithelium following acute bronchiolitis in infancy
J Y W Wong1, A Rutman, C O'Callaghan
1Department of Child Health, University of Leicester, School of Medicine, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, P O Box 65, Leicester LE2 7LX, UK.
Insights
Infant respiratory cilia and epithelium take 13-17 weeks to recover after viral bronchiolitis. Inhaled steroids did not speed up this recovery process in the study.
Area of Science:
- Pediatric Respiratory Medicine
- Cell Biology
- Clinical Trials
Background:
- Viral bronchiolitis significantly impacts infant respiratory health.
- Longitudinal changes in ciliated respiratory epithelium post-bronchiolitis are poorly understood.
Purpose of the Study:
- To determine the recovery time of ciliated respiratory epithelium following infant viral bronchiolitis.
- To investigate the efficacy of inhaled steroids in accelerating epithelial recovery.
Main Methods:
- A clinical trial involving 31 infants treated with inhaled fluticasone (FP) or placebo for 12 weeks.
- Nasal biopsy specimens analyzed for ciliary beat frequency (CBF) and ultrastructure via transmission electron microscopy.
- Comparison with 19 healthy children as controls, with measurements taken at baseline and 3, 6, 12, and 24 weeks.
Main Results:
- Ciliary beat frequency (CBF) in bronchiolitis infants gradually normalized over 24 weeks.
- Epithelial ultrastructure abnormalities persisted for an average of 13.1 to 16.7 weeks.
- Inhaled fluticasone showed no significant impact on CBF or epithelial recovery compared to placebo.
Conclusions:
- Infant ciliated epithelium requires an extended period (13-17 weeks) to normalize after viral bronchiolitis.
- Current inhaled steroid treatment protocols do not appear to expedite the natural healing process of the respiratory epithelium.
Background:
Little is known about the longitudinal changes in the ciliated respiratory epithelium of infants following viral bronchiolitis. A study was undertaken to investigate the time required for the ciliated epithelium to return to normal following bronchiolitis in infants treated with inhaled steroids or placebo.
Methods:
Thirty one previously healthy term infants were studied as part of a clinical trial to determine the effect of 12 weeks of treatment with inhaled fluticasone (FP) or placebo via a spacer device (17 FP, 14 placebo). Nineteen healthy children aged 0-6 years previously studied in our department were used as controls. Nasal biopsy specimens were taken from infants with bronchiolitis and ciliary beat frequency (CBF) was measured before treatment and repeated 3, 6, 12, and 24 weeks later. The epithelial ultrastructure was examined by transmission electron microscopy and a normal errors mixed model based on normal controls was used to examine the time for cilia to return to normal in bronchiolitic infants.
Results:
The mean CBF of infants with bronchiolitis (in Hz) at weeks 0, 3, 6, 12, and 24 were 0.5 (n = 4), 10.9 (n = 4), 12.0 (n = 9), 11.9 (n = 8), and 12.1 (n = 7) in the placebo group and 10.6 (n = 6), 11.4 (n = 9), 8.8 (n = 8), 10.9 (n = 4), and 13.2 (n = 7) in the FP group. The time for the epithelial ultrastructure to normalise was as follows: epithelial integrity score (13.1 weeks), % ciliated cells with loss of cilia (14.0 weeks), and % epithelial cells with abnormalities in projection (16.7 weeks) or mitochondria (15.9 weeks). Inhaled steroids had no significant effects on CBF or epithelial ultrastructure.
Conclusion:
Ciliary loss and epithelial abnormalities persist on average for 13-17 weeks following acute bronchiolitis in infancy.
Related Concept Videos
Pulmonary Cycle: Exhalation
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Breathing
Chronic Obstructive Pulmonary Disease II: Emphysema
Respiratory Syncytial Virus Disease

